Breaking News
September 25, 2018 - Lung cancer patients treated with invasive surgery more likely to become chronic opioid users
September 25, 2018 - Oxford VR raises £3.2m to boost innovation in VR for mental health problems
September 25, 2018 - Gene therapy approach could help treat mitochondrial diseases
September 25, 2018 - Few Yogurt Products Qualify As Low-Sugar
September 25, 2018 - Eye disease can cause blindness, and it’s on the rise
September 25, 2018 - Pawnshop density linked to gun-related suicides, Stanford study finds
September 25, 2018 - Pioneering procedure for common prostate condition offered by The London Clinic
September 25, 2018 - Number of people with respiratory diseases likely to increase if UK air pollution remains unchecked
September 25, 2018 - FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
September 24, 2018 - Drug combination offers more effective care for patients suffering miscarriage
September 24, 2018 - Tallness linked to varicose veins, Stanford study says
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Ecstasy drug makes octopuses more social
September 24, 2018 - Immediate compression therapy could cut risk of complications after deep-vein thrombosis
September 24, 2018 - Transcatheter mitral valve repair reduces mortality for patients with mitral regurgitation
September 24, 2018 - First intracranial aneurysm patients treated with BRAVO Flow Diverter after CE mark approval
September 24, 2018 - ‘Physicians of the mouth’? Dentists absorb the medical billing drill
September 24, 2018 - People more likely to believe those with confident tone of voice than with accent
September 24, 2018 - Harmony Biosciences Presents 5-Year Data On Pitolisant At International Narcolepsy Symposium
September 24, 2018 - Blood test may identify gestational diabetes risk in first trimester
September 24, 2018 - Height may be risk factor for varicose veins | News Center
September 24, 2018 - King’s commemorates opening of new NMR facility with one-day symposium
September 24, 2018 - Eisai receives approval for partial label change of DC Bead device for transcatheter arterial embolization
September 24, 2018 - High-resolution genomic map gives scientists unprecedented view of brain development
September 24, 2018 - Researchers find impact of neurobehavioral symptoms on employment in adults with TBI
September 24, 2018 - Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD
September 24, 2018 - First evaluation of benefits, harms of Alzheimer’s screening for family members of older adults
September 24, 2018 - Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System
September 24, 2018 - Children of mothers using cannabis may start using it at an earlier age, finds study
September 24, 2018 - Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US
September 24, 2018 - Most patients who underwent transcatheter valve replacement experience prosthesis-patient mismatch
September 24, 2018 - Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone
September 24, 2018 - New study provides basis for Air Canada to change its facial hair policy for aircrew
September 24, 2018 - Infant walkers lead to thousands of emergency visits for babies
September 24, 2018 - Genes predicting person’s height may provide clues about causes of varicose veins
September 24, 2018 - EPA Plan Will Maintain Carbon Emissions From Power Plants
September 24, 2018 - Characterizing pig hippocampus could improve translational neuroscience
September 24, 2018 - Element3 Health reports social and mental engagement play key role in overall health
September 24, 2018 - Paralympic medalists support Fight for Sight’s unique virtual event
September 24, 2018 - ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma
September 24, 2018 - Public awareness of urological conditions found to be alarmingly low across Europe
September 24, 2018 - Fitter Folks Suffer Milder Strokes: Study
September 24, 2018 - Novel botulinum toxin compound relieves chronic pain
September 24, 2018 - CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents
September 24, 2018 - National Friendly’s private medical insurance is a hit with women living in the South East
September 24, 2018 - Academics receive prestigious awards for achievements in blood pressure research
September 24, 2018 - Obese pregnant women can restrict weight gain safely with proper nutrition guidance
September 24, 2018 - CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer
September 24, 2018 - China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma
September 24, 2018 - A new approach for finding Alzheimer’s treatments
September 24, 2018 - USC research uncovers previously unknown genetic risk factor for dementia
September 24, 2018 - Study examining mental health among students finds significant disparities in treatment across race
September 24, 2018 - Breakthrough discovery paves way for future test to identify drowsy drivers
September 24, 2018 - Transcatheter mitral-valve repair in patients with heart failure
September 24, 2018 - Study opens new avenues for treatment of Laing distal myopathy
September 24, 2018 - Stroke Facts | cdc.gov
September 24, 2018 - Sarcolipin tricks muscle cells into using more energy, burning fat
September 24, 2018 - Enrollment in opioid controlled substance agreement reduces primary care visits
September 24, 2018 - UTA researchers patent new smart seat cushion technology that helps prevent painful ulcers
September 24, 2018 - Second HPV-Related Primary Cancers Common in Survivors
September 24, 2018 - How a virus destabilizes the genome
September 24, 2018 - Old letters provide insight into Spanish flu pandemic horror
September 23, 2018 - Smart textile-based soft robotic exosuit helps wearers save energy and traverse difficult terrain
September 23, 2018 - New research hub to drive radical change in development and manufacturing of vaccines
September 23, 2018 - AHA: For Hispanics, Neighborhood May Be Key Factor in Heart Disease Risk
September 23, 2018 - Excessive airway nerves tied to more severe asthma symptoms, study finds
September 23, 2018 - Study highlights need to remain vigilant in maintaining key infection control processes
Inhaled Nitrite Flops as HFpEF Therapy

Inhaled Nitrite Flops as HFpEF Therapy

image_pdfDownload PDFimage_print

ORLANDO — An inhaled inorganic nitrite improved neither exercise capacity nor general clinical status for patients with heart failure with preserved ejection fraction (HFpEF), according to the INDIE-HFpEF trial.

Delivery of the compound by nebulizer did not improve peak exercise capacity on cardiopulmonary exercise testing, as it left patients with the same 14 ml/min/kg VO2 as their peers randomized to placebo (P=0.27), Barry Borlaug, MD, of the Mayo Clinic in Rochester, Minnesota, reported at the annual American College of Cardiology meeting here.

The nitrite did not increase daily activity or patient-reported quality of life. It also failed to improve heart failure symptom severity and cardiac congestion. But nor was there an uptick in severe adverse events with the inhaled compound, the presenter said during the late-breaking trial session.

“These data do not support use of inhaled, nebulized inorganic nitrite for symptom relief in patients with HFpEF,” he concluded. The hope was that inorganic nitrite, which restores nitric oxide, might improve exercise capacity and clinical status in patients with HFpEF given evidence suggesting that impaired nitric oxide signalling may drive heart failure.

“HFpEF remains an enormous unmet public health problem. Further study is required to determine the potential efficacy of other nitric oxide-providing therapies in HFpEF,” Borlaug urged.

Previously, researchers had found that organic nitrate supplementation was poorly tolerated and in fact reduced patient activity levels.

Session panelist Lee Goldberg, MD, MPH, of the Hospital of the University of Pennsylvania in Philadelphia, said he was left wondering after the INDIE-HFpEF presentation if the inhaled nitrite was actually being absorbed and whether researchers have been targeting the wrong pathway in HFpEF all along.

The trial “certainly doesn’t support the hypothesis” that it’s nitric oxide that’s driving HFpEF, the presenter responded. Yet there are several ways to target it upstream or downstream, he said, making him unwilling to discard therapies aimed at nitric oxide just yet.

Click here for video comments from study authors and discussants at ACC 2018.

After all, it is possible that the inorganic nitrite could have worked with a longer duration of exposure or perhaps in combination with exercise training, Borlaug said. Oral nitrate is another alternative, as it is converted by bacteria in the mouth to nitrite, that is now being tested in other studies, according to the investigator.

For the INDIE-HFpEF trial, researchers across 20 centers participating in the NHLBI Heart Failure Clinical Research Network randomized 105 participants in their double-blind crossover study. Patients started with 4 weeks on inhaled nitrite or placebo (three times a day) before a switch to 4 weeks on placebo or vice versa.

Heart failure patients were included if they had reduced exercise capacity with New York Heart Association class II-IV symptoms and an ejection fraction of at least 50%. The nitrite-first group had more women and more patients with diabetes.

“That there is an unmet need for a therapy to improve the outcomes of these patients is an understatement,” commented James Januzzi, MD, of Massachusetts General Hospital in Boston, at a press conference. “When we say we have few therapies … we mean we have no therapies to improve outcomes in these patients.”

Januzzi said the study was “exceptionally important” while arguing that it doesn’t close the door on nitric oxide therapy given its “very strong scientific basis.”

“There’s still a lot of work to do in this space and the study does point in a direction for us. Someone is going to figure it out sooner or later,” he predicted.

Borlaug disclosed receiving consultant fees or honoraria from Actelion, Amgen, Arteriomedix, Merck, and MyoKardia; and research grants from AstraZeneca, Corvia, GlaxoSmithKline, Medtronic, and Mesoblast.

Goldberg declared consultant fees, honoraria, or both from Medtronic and research grants from Respircardia.

Januzzi reported consultant fees and/or honoraria from Abbott Laboratories, Critical Diagnostics, Phillips, and Roche Diagnostics; serving on Data Safety Monitoring Boards for AbbVie, Amgen, Boeringer Ingelheim, Janssen, and Siemens; and receipt of research grants from Cleveland Heart Labs, Novartis, Prevencio, and Singulex.

2018-12-03T00:00:00-0500

last updated

Tagged with:

About author

Related Articles